| Name | Title | Contact Details |
|---|---|---|
Andrew Karl |
Chief Marketing Officer | Profile |
American Global is a prominent privately held insurance and surety brokerage firm based in Miami, Florida. With over 100 locations worldwide, the company specializes in construction risk management. Their mission focuses on understanding client needs and creating tailored solutions, fostering long-term partnerships to enhance the brokerage experience. The firm offers a wide range of services, including managing complex surety programs, providing consultative insurance solutions, and designing captive finance options. They also create Controlled Insurance Programs (CIPs) and Subcontractor Default Insurance (SDI) programs to help clients minimize costs and manage risks effectively. American Global serves a diverse clientele in the construction industry, including general contractors and construction management firms. The company promotes a culture of innovation and collaboration, encouraging employees to contribute to the future of construction brokerage. American Global has been recognized as one of the "Best Places to Work" by Business Insurance for two consecutive years, reflecting their commitment to employee satisfaction and development.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Somos una empresa internacional especializada en startups y empresas tech de LATAM. Acompañamos el crecimiento acelerado de los founders garantizándoles en cada etapa el cumplimiento de todos sus compromisos financieros, contables, impositivos y legales en cada país en el que operan. Nuestras soluciones contemplan servicios de compliance, impuestos internacionales, softlanding, CFO Services, transaction services y legal services. Nos caracterizamos por nuestra velocidad de respuesta, profesionalismo y calidad en la ejecución.